Cannabis Bioscience International notifies availability of press release

CANNABIS BIOSCIENCE INTL HLDGS

CBIH

0.00

Cannabis Bioscience International Holdings (OTCID: CBIH) published a press release on July 20, 2026, unveiling an intranasal nanoemulsion platform for Alzheimer’s research.
Platform targets delivery of selected cannabinoid-based or natural neuroactive compounds, positioning a multi-pathway approach rather than a single-target strategy.
Release cites 7.4 million Americans age 65+ living with Alzheimer’s dementia in 2026, rising to 13.8 million by 2060 without breakthroughs.
Alzheimer’s-related health and long-term care spending estimated at $409 billion in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannabis Bioscience International Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607200700NEWSFILECNPR____20260720_305652_1) on July 20, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.